Efficacy and pharmacokinetics of the combination of etravirine plus raltegravir as novel dual antiretroviral maintenance regimen in HIV-infected patients.

[1]  C. Quereda,et al.  Etravirine-based antiretroviral therapy in HIV/hepatitis C virus coinfected advanced fibrosis patients receiving triple therapy against hepatitis C virus with telaprevir. , 2014, AIDS.

[2]  B. Hernández-Novoa,et al.  Interpreting the reasons for the choice and changing of two drug regimens in an observational cohort: comparison of a ritonavir‐boosted protease inhibitor‐based versus a nonnucleoside reverse transcriptase inhibitor‐based first‐line regimen , 2014, HIV medicine.

[3]  F. Villarroya,et al.  A 48-Week Study of Fat Molecular Alterations in HIV Naive Patients Starting Tenofovir/Emtricitabine With Lopinavir/Ritonavir or Efavirenz , 2014, Journal of acquired immune deficiency syndromes.

[4]  C. Katlama,et al.  Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study. , 2014, The Journal of antimicrobial chemotherapy.

[5]  J. Gatell,et al.  Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study. , 2014, The Journal of antimicrobial chemotherapy.

[6]  B. Clotet,et al.  Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. , 2013, The Lancet. Infectious diseases.

[7]  J. Casado.  Liver toxicity in HIV-infected patients receiving novel second-generation nonnucleoside reverse transcriptase inhibitors etravirine and rilpivirine. , 2013, AIDS reviews.

[8]  Peter Reiss,et al.  Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study. , 2013, The Journal of infectious diseases.

[9]  S. Moreno,et al.  Lipid-Lowering Effect and Efficacy After Switching to Etravirine in HIV-Infected Patients With Intolerance to Suppressive HAART , 2013, HIV clinical trials.

[10]  R. Tubiana,et al.  Dual Raltegravir/Etravirine Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy , 2012, Antiviral therapy.

[11]  J. Eron,et al.  Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients , 2012, Antimicrobial Agents and Chemotherapy.

[12]  J. Gatell,et al.  Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study , 2010, AIDS.

[13]  C. Solas,et al.  Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases. , 2009, AIDS.

[14]  J. Poirier,et al.  Quantification of the HIV-integrase inhibitor raltegravir (MK-0518) in human plasma by high-performance liquid chromatography with fluorescence detection. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[15]  V. Soriano,et al.  Combinations of nucleoside/nucleotide analogues for HIV therapy. , 2004, AIDS reviews.

[16]  M. Schöller-Gyüre,et al.  Pharmacokinetic Interactions between Etravirine and Non-Antiretroviral Drugs , 2011, Clinical pharmacokinetics.

[17]  Amalio Telenti,et al.  Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .